quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:19:00·189d
PRRelease
Biomerica Inc. logo
Henry Schein Inc. logo

Henry Schein and Biomerica Enter into Marketing Services Agreement for Biomerica's inFoods® IBS Test in the U.S.

BMRA· Biomerica Inc.HSIC· Henry Schein Inc.
Health Care
Original source

Companies

  • BMRA
    Biomerica Inc.
    Health Care
  • HSIC
    Henry Schein Inc.
    Health Care

Recent analyst ratings

  • Apr 16HSICUpdateBTIG Research-
  • Apr 15HSICUpdateCitigroup$100.00
  • Feb 23HSICUpdateRobert W. Baird$100.00
  • Dec 9HSICUpdateBarclays$86.00
  • Aug 26HSICUpdateEvercore ISI$83.00
  • Jul 25HSICUpdateStifel$75.00

Related

  • PR2d
    Henry Schein to Webcast First Quarter 2026 Conference Call on Tuesday, May 5, 2026, at 8:00 A.M. ET
  • PR7d
    Biomerica Announces Medicare Administrative Contractor Confirmation of Individual Claim Review for inFoods® IBS, Opening a Scalable Medicare Commercialization Pathway
  • ANALYST7d
    BTIG Research initiated coverage on Henry Schein
  • ANALYST8d
    Citigroup initiated coverage on Henry Schein with a new price target
  • PR9d
    Biomerica Launches inFoods® IBS in Canada Through Partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs
  • PR10d
    Biomerica Reports Third Quarter Fiscal 2026 Financial Results
  • SEC10d
    SEC Form 10-Q filed by Biomerica Inc.
  • SEC15d
    SEC Form DEFA14A filed by Henry Schein Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022